Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex PK/PD in Pediatric Rocuronium Reversal
NCT04347486Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Apr 2020
- Primary completion
- Dec 2021
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Sugammadex in neuromuscular blockade (NMB) (4 arms), sponsored by Seoul National University Hospital. Primary endpoint: Time to neuromuscular recovery at 1 hour. Started Apr 2020; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT04347486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04347486.